Longeveron Plunges 11.51% on Revenue Drop

On August 14, 2025, Longeveron's stock price experienced a significant drop of 11.51% in pre-market trading, reflecting a notable decline in investor sentiment.

Longeveron Inc. has been facing a series of challenges that have contributed to its recent stock performance. The company reported a 32% revenue drop in Q2 2025, which has raised concerns about its financial stability. With nearly $12.7 million in equity remaining as of June 30, 2025, and further cost increases expected, Longeveron is likely to need new capital to sustain its operations.

Despite these challenges, there have been some positive developments for Longeveron. The company's stock surged by 25.89% following the announcement of positive results in a trial of treatment for a rare congenital heart defect in infants. This news has provided a glimmer of hope for investors, who are closely monitoring the company's progress in this area.

Analysts have given Longeveron a consensus rating of Buy, with an average rating score of 3.25 based on three buy ratings. However, the company's stock has been oversold on the RSI14, which may present a buying opportunity for investors who are willing to take on some risk.